Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells

The resistance to tyrosine kinase inhibitors is currently a major problem for chronic myeloid leukemia (CML) treatment and HSPA8 is highly expressed and a hallmark of poor prognosis in several human cancers. However, its role in imatinib-resistant CML (IR-CML) cells remains undetermined. Here, we de...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Experimental cell research 2021-08, Vol.405 (2), p.112708-112708, Article 112708
Hauptverfasser:	Liu, Zhen, Zheng, Wenlong, Liu, Yuan, Zhou, Binghe, Zhang, Yuqing, Wang, Fan
Format:	Artikel
Sprache:	eng
Schlagworte:	60 APPLIED LIFE SCIENCES ABLATION APOPTOSIS BCR-ABL CELL CYCLE CELL PROLIFERATION Chronic myeloid leukemia HSPA8 Imatinib IN VITRO INHIBITION MYELOID LEUKEMIA PHOSPHOTRANSFERASES TYROSINE
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!